Breast cancer stands as the most frequent malignancy and leading cause of death among women. Early and accurate detection of this pathology represents a crucial factor in enhancing both incidence and mortality rates. Ultrasound (US) examination has been extensively adopted in clinical practice due to its non-invasiveness, affordability, ease of implementation, and wide accessibility, thus representing a valuable first-line diagnostic tool for the study of the mammary gland. In this scenario, recent developments in nanomedicine are paving the way for new interpretations and applications of US diagnostics, which are becoming increasingly personalized based on the molecular phenotype of each tumor, allowing for more precise and accurate evaluations. This review highlights the current state-of-the-art of US diagnosis of breast cancer, as well as the recent advancements related to the application of US contrast agents to the field of molecular diagnostics, still under preclinical study.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632334PMC
http://dx.doi.org/10.1007/s40477-023-00809-0DOI Listing

Publication Analysis

Top Keywords

breast cancer
12
contrast agents
8
exploring potential
4
potential contrast
4
agents breast
4
cancer echography
4
echography current
4
current state
4
state future
4
future directions
4

Similar Publications

Background: Tumor metastasis is one of the main causes of death in cancer patients; however, the mechanism controlling metastasis is unclear. The posttranscriptional regulation of metastasis-related genes mediated by AT-rich interactive domain-containing protein 4A (Arid4a), an RNA-binding protein (RBP), has not been elucidated.

Methods: Bioinformatic analysis, qRT-PCR, immunohistochemistry, and immunoblotting were employed to determine the expression of Arid4a in breast tumor tissues and its association with the survival of cancer patients.

View Article and Find Full Text PDF

In recent years, tumor immunotherapy has made significant breakthroughs in the treatment of malignant tumors. However, individual differences in efficacy have been observed in clinical practice. There is increasing evidence that gut microbial metabolites influence the efficacy of distal tumor immunotherapy via the gut-liver axis, the gut-brain axis and the gut-breast axis, a process that may involve modulating the expression of immune cells and cytokines in the tumor microenvironment (TME).

View Article and Find Full Text PDF

High tumour mutational burden (TMB-high), identified through comprehensive genomic profiling (CGP), is a biomarker that predicts the efficacy of immune checkpoint inhibitors. CGP testing is recommended for rare cancers with limited effective treatment options. Here, we provide the first report of a malignant phyllodes tumour of the breast demonstrating TMB-high status and effective treatment with pembrolizumab.

View Article and Find Full Text PDF
Article Synopsis
  • Advances in breast cancer treatment have not significantly improved outcomes for metastatic cases, which still lead to high mortality rates.
  • Physical activity has been linked to reduced breast cancer risk and improved treatment outcomes, prompting a study on its effects on metastatic triple negative breast cancer (TNBC).
  • Results show that increasing physical activity after surgical interventions can significantly enhance metastasis-free survival in mice, suggesting exercise may play a crucial role in delaying cancer progression.
View Article and Find Full Text PDF

Unlabelled: Nasal polyp (NP) is a pathological benign mass that affects the nasal cavity and paranasal sinuses. This lesion is occasionally associated with chronic rhinosinusitis (CRS), which is named chronic rhinosinusitis with nasal polyps (CRSwNP). Proliferating cell nuclear antigen (PCNA) indicates abnormal cell proliferation which may help assess the nasopharyngeal lesions and upper airway cancers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!